Dr. Danuta Radzioch, Ph.D., is a Full Professor at the Faculty of Medicine of McGill University, Department of Medicine and Department of Human Genetics, Montreal, Canada. She defended her Ph.D. dissertation in the field of molecular biology of cancer at the Jagiellonian University (1982), Cracow, Poland and completed postdoctoral training (1984-1987) at the National Institute of Health, National Cancer Institute (Frederick Cancer Research Facility, USA) in the field of molecular immunoregulation. Dr. Radzioch worked at the Frederick Cancer Research Facility until 1989. In 1989 she had become appointed as an Assistant Professor of Medicine at McGill University. She became an Associate Professor with Tenure in 1996 and full Professor in 2003 at the Department of Experimental Medicine and at the Department of Human Genetics. Dr. Radzioch published 145 scientific papers and 6 books and book chapters. She has co-authored five patents and two Orphan Drug designation applications: one already approved by U.S. Food and Drug Administration (FDA) and the other submitted to European Medicines Evaluation Agency (EMEA) for a new promising drug called fenretinide, a derivative of Vitamin A, for the treatment of CF patients suffering from chronic bacterial lung infections with P. aeruginosa. Her current fields of research are focused on regulation of inflammatory response in Cystic fibrosis, genetic regulation of airway hyperresponsiveness and allergic asthma, safety of novel methods of delivery of anticancer drugs and on the molecular mechanisms of gene expression regulation during the course of infection and inflammation. Her current research explores transcriptional regulation which involves chromatin remodelling and posttranscriptional processes of gene expression regulation by the RNA-binding proteins.